Fiscal Estimate - 2009 Session

\boxtimes	Original		Updated		Corrected		Supple	mental		
LRB	Number	09-1836/1		Intro	duction Nu	mber <i>i</i>	AB-048	2		
Descri The mi		orice of prescri	otion drugs							
Fiscal	Effect			,						
	No State Fiscandeterminate Increase E Appropriat Decrease Appropriat Create Ne	Existing ions Existing	Increase Revenue Decrease Revenue	s Existing	to a	crease Cost absorb with Yes crease Cos	nin agency			
Local: No Local Government Costs Indeterminate 1. Increase Costs Permissive Mandatory 2. Decrease Costs Permissive Mandatory Permissive Mandatory Permissive Mandatory Permissive Mandatory Permissive Mandatory Districts 5. Types of Local Government Units Affected Towns Counties Others School Districts Districts										
Fund Sources Affected Affected Ch. 20 Appropriations GPR FED PRO PRS SEG SEGS										
Agend	y/Prepared I	Зу	Aut	horized	Signature			Date		
DATCP/ Kevin LeRoy (608) 224-4928 Bill W					Walker (608) 224-4353					

Fiscal Estimate Narratives DATCP 10/8/2009

LRB Number	09-1836/1	Introduction Number	AB-0482	Estimate Type	Original					
Description										
The minimum sale price of prescription drugs										

Assumptions Used in Arriving at Fiscal Estimate

The Unfair Sales Act prohibits retailers and wholesalers from selling products at a price that is less than the sellers "cost" as the term is defined in the act. (For certain product, the statutory definition of "cost" includes a minimum markup to represent the "cost of doing business." However, for most products, including prescription drugs, "cost" is defined, generally, as the price paid by the seller.)

Current law contains a list of exceptions to the prohibition of selling merchandise below cost. For example, current exceptions include meeting the price of a competitor, seasonal clearance sales, going out of business sales, etc. This proposed bill would add an additional exception allowing for sales below cost as long as the merchandise sold is prescription drugs.

DATCP is the agency primarily responsible for state enforcement of the Unfair Sales Sales Act. Generally, DATCP conducts investigations of alleged Unfair Sales Act violations based on complaints. In recent years we have not received any complaints relating to allegedly selling prescription drugs at a price that is less than cost. Therefore, we estimate that this bill would not have any significant fiscal effect on DATCP.

Long-Range Fiscal Implications